Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Model System Allows Study of Cell Cycle Checkpoint Proteins

By LabMedica International staff writers
Posted on 01 Dec 2009
Cancer researchers have created a mouse model system that allows them to study cell cycle checkpoint proteins in healthy and cancerous mammary gland tissues.

Checkpoint proteins monitor the status of the cell genome and, in response to DNA damage, halt cell cycle progression and promote repair or apoptosis, thereby preventing mutation accumulation and suppressing tumor development. More...
The checkpoint protein Hus1 associates with the proteins Rad9 and Rad1 to form the 9-1-1 complex, which localizes to DNA lesions and promotes DNA damage signaling and repair.

Attempts to genetically engineer mice to lack Hus1 failed, as complete inactivation of Hus1 resulted in embryonic lethality. Therefore, investigators at the Cornell University College of Veterinary Medicine (Ithaca, NY, USA) developed a system for regulated Hus1 inactivation in the mouse mammary gland to examine roles for Hus1 in tissue homeostasis and tumor suppression.

They reported in the Nov. 16, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) that Hus1 inactivation in the mammary epithelium resulted in genome damage that induced apoptosis and led to depletion of cells lacking Hus1 from the mammary gland. In cancerous tissue with an inactive form of the tumor-suppressor protein p53, there was a delay in the clearance of cells lacking Hus1 that caused the accumulation of damaged, dying cells in the mammary gland.

"Our work contributes to an important new understanding of cancer cells and their weaknesses," said senior author Dr. Robert Weiss, professor of molecular genetics at the Cornell University College of Veterinary Medicine. "The mutations that allow cancer cells to divide uncontrollably also make the cancer cells more dependent on certain cellular processes. We were able to exploit one such dependency of p53-deficient cells and could efficiently kill these cells by inhibiting Hus1. We have proven the power of inhibiting both pathways in normal tissue. Now we want to extend our knowledge to cancerous tissue and determine if the loss of Hus1 will impact the ability of cancers with p53 mutations to take hold and grow."

Related Links:
Cornell University College of Veterinary Medicine



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.